Lower Proportion of CD45R0+ Cells and Deficient Interleukin-10 Production by Formula-Fed Infants, Compared With Human-Fed, Is Corrected With Supplementation of Long-Chain Polyunsaturated Fatty Acids

Field, Catherine J.; Thomson, Christine E.; Aerde, John E. Van; Parrott, A.; Euler, Arthur R.; Lien, Eric L.; Clandinin, Michael T.

doi:10.1097/00005176-200009000-00017

Cited by 136 publications

(120 citation statements)

References 53 publications

Supporting

Mentioning

107

Contrasting

Unclassified

Order By: Relevance

“…Isolated cells (200 000 cells per well) were used to determine the cell phenotype using a two-colour direct immunofluorescence (Field et al, 2000). Antibodies used were CD3, CD4, CD8, CD25, CD28, CD62L, CD71, CD80, CD45RA (BD Bioscience, Mississauga, ON, Canada) and OX12 (Cedarlane, Hornby, ON, Canada); Streptavidin QR (Sigma, Oakville, ON, Canada) was added to all biotin-labelled antibodies.…”

Section: Discussionmentioning

confidence: 99%

“…Antibodies used were CD3, CD4, CD8, CD25, CD28, CD62L, CD71, CD80, CD45RA (BD Bioscience, Mississauga, ON, Canada) and OX12 (Cedarlane, Hornby, ON, Canada); Streptavidin QR (Sigma, Oakville, ON, Canada) was added to all biotin-labelled antibodies. The percentage of cells expressing each antibody marker was determined by flow cytometry (FacScan, Becton Dickinson, Sunnyvale, CA, USA) (Field et al, 2000). It was not always possible to perform every phenotype assay on each rat because of the variation in total yield of tissue; n for each assay is indicated in result tables.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy

et al. 2009

View full text Add to dashboard Cite

Infectious complications are a major cause of morbidity and mortality from dose-intensive cancer chemotherapy. In spite of the importance of intestinal bacteria translocation in these infections, information about the effect of high-dose chemotherapy on gut mucosal immunity is minimal. We studied prophylactic ciprofloxacin (Cipro) treatment on irinotecan (CPT-11) toxicity and host immunity in rats bearing Ward colon tumour. Cipro abolished chemotherapy-related mortality, which was 45% in animals that were not treated with Cipro. Although Cipro reduced body weight loss and muscle wasting, it was unable to prevent severe late-onset diarrhoea. Seven days after CPT-11, splenocytes were unable to proliferate (stimulation index ¼ 0.10 ± 0.02) and produce proliferative and inflammatory cytokines (i.e., Interleukin (IL)-2, interferon-g (IFN-g), tumour necrosis factor-a (TNF-a) IL-1b, IL-6) on mitogen stimulation in vitro (Po0.05 vs controls), whereas mesenteric lymph node (MLN) cells showed a hyper-proliferative response and a hyper-production of pro-inflammatory cytokines on mitogen stimulation. This suggests compartmentalised effects by CPT-11 chemotherapy on systemic and intestinal immunity. Cipro normalised the hyper-responsiveness of MLN cells, and in the spleen, it partially restored the proliferative response and normalised depressed production of IL-1b and IL-6. Taken together, Cipro prevented infectious challenges associated with immune hypo-responsiveness in systemic immune compartments, and it may also alleviate excessive pro-inflammatory responses mediating local gut injury.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy

et al. 2009

View full text Add to dashboard Cite

show abstract

“…25 The following pre-labelled monoclonal antibodies were used: CD3 and CD28 (FITC-labelled); CD4, CD8, CD3, CD11b/c and OX12 (PE-labelled); and CD25 and CD8 (biotin-labelled). All antibodies were purchased from BD Biosciences, PharMingen (Mississauga, ON, Canada) except CD4, and OX12, which were purchased from Serotec (Cedarlane Laboratories Ltd, Hornby, ON, Canada).…”

Section: Phenotype Analysismentioning

confidence: 99%

Effects of feeding fish oil on mesenteric lymph node cytokine responses in obese leptin receptor-deficient JCR:LA-cp rats

2008

View full text Add to dashboard Cite

Objective: Aberrant immune responses have been identified in obesity; however, immune cells of lymph nodes residing in the inflammatory environment of visceral adipose tissue have been largely overlooked. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) can reduce inflammation and modify T-cell function and therefore may improve immune function in obesity. Thus, we determined the effects of feeding fish oil (FO) containing EPA and DHA on mesenteric lymph node (MLN) immune cell function. Methods: In this study, 14-week-old obese, leptin receptor-deficient JCR:LA-cp rats (cp/cp) (n ¼ 10 per group) were randomized to one of three nutritionally adequate diets for 3 weeks: control (ctl, 0% EPA þ DHA), low FO (LFO, 0.8% w/w EPA þ DHA) or high FO (HFO, 1.4% w/w EPA þ DHA). Lean JCR:LA-cp (Cp/cp or Cp/Cp) rats (n ¼ 5) were fed ctl diet. MLN cell phospholipid (PL) fatty acid composition, phenotypes and cytokine production were measured. Results: Obese ctl rats produced more IL-1b, IL-4 and IL-10, despite a higher proportion of (nÀ3) polyunsaturated fatty acids (PUFAs) and a lower (nÀ6):(nÀ3) PUFA ratio in MLN PL compared with lean ctl rats (Po0.05). Concanavalin A-stimulated IL-2 production did not differ from lean rats even though obese ctl rats had a lower proportion of CD4 þ CD25 þ cells (Po0.05). Feeding FO to obese rats increased the incorporation of (nÀ3) PUFA into MLN PL and normalized production of IL-1b (HFO only), IL-4 and IL-10 to the levels similar to lean ctl rats (Po0.05). Conclusion: We demonstrate for the first time that obese JCR:LA-cp rats have impaired responses of MLN immune cells to mitogen stimulation and altered PL fatty acid composition. Feeding FO lowered the ex vivo inflammatory response (HFO only) and production of Th2 cytokines, without changing IL-2 production from ConA-stimulated splenocytes, which may occur independent of leptin signalling.

show abstract

“…Binding of MKPs to their MAPK substrates increases phosphatase activity (Camps et al, 1998a;Hutter et al, 2000;Slack et al, 2001) and this is due to stabilization of the active enzyme-substrate complex (Field et al, 2000). MKP-3 exhibits high fidelity to its substrate ERK1/2 and upon binding its catalytic activity is enhanced (Camps et al, 1998b).…”

Section: Mapk Phosphatases In Skeletal Muscle Function and Muscular Dmentioning

confidence: 99%

Mitogen-Activated Protein Kinases and Mitogen-Activated Protein Kinase Phosphatases in Regenerative Myogenesis and Muscular Dystrophy

Shi¹,

Bennett²

2012

Muscular Dystrophy

View full text Add to dashboard Cite

Lower Proportion of CD45R0+ Cells and Deficient Interleukin-10 Production by Formula-Fed Infants, Compared With Human-Fed, Is Corrected With Supplementation of Long-Chain Polyunsaturated Fatty Acids

Abstract: Adding LCP to a preterm infant formula resulted in lymphocyte populations, phospholipid composition, cytokine production, and antigen maturity that are more consistent with that in human milk-fed infants. This may affect the ability of the infant to respond to immune challenges.

Cited by 136 publications

References 53 publications

Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy

Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy

Effects of feeding fish oil on mesenteric lymph node cytokine responses in obese leptin receptor-deficient JCR:LA-cp rats

Mitogen-Activated Protein Kinases and Mitogen-Activated Protein Kinase Phosphatases in Regenerative Myogenesis and Muscular Dystrophy

Contact Info

Product

Resources

About